4CPS-335 Experience in the use of tocilizumab in patients with COVID-19. Has it really been effective?

Background and importanceTocilizumab is being used to treat severe SARS-CoV-2 pneumonia.Aim and objectivesTo analyse the efficacy of tocilizumab in patients with severe SARS-CoV-2 pneumonia during the inflammatory phase of the disease.Material and methodsAn observational retrospective study was cond...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2021-03, Vol.28 (Suppl 1), p.A82-A82
Hauptverfasser:	Valdazo Martín, C, Ramon Rigau, N, Rosado Ancín, M, Urrestarazu Larrañaga, M, Santaolalla Sánchez, A, Hernanz Chaves, R, García Albás, JJ, Gómez Ugartondo, E, Guisasola Ron, L, Arenales Cáceres, P, Martínez Martínez, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Conflicts of interest Immunosuppressive agents Monoclonal antibodies Pneumonia Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background and importanceTocilizumab is being used to treat severe SARS-CoV-2 pneumonia.Aim and objectivesTo analyse the efficacy of tocilizumab in patients with severe SARS-CoV-2 pneumonia during the inflammatory phase of the disease.Material and methodsAn observational retrospective study was conducted between 16 March and 22 April 2020, which included 75 patients (57 men, mean age 67.7 years) treated with tocilizumab. Criteria for severe pneumonia were: failure of at least one organ, oxygen saturation with ambient air
ISSN:	2047-9956 2047-9964
DOI:	10.1136/ejhpharm-2021-eahpconf.167